238 related articles for article (PubMed ID: 32651110)
1. Role of the Bone Marrow Milieu in Multiple Myeloma Progression and Therapeutic Resistance.
Ho M; Goh CY; Patel A; Staunton S; O'Connor R; Godeau M; Bianchi G
Clin Lymphoma Myeloma Leuk; 2020 Oct; 20(10):e752-e768. PubMed ID: 32651110
[TBL] [Abstract][Full Text] [Related]
2. Targeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma.
Podar K; Jager D
Curr Cancer Drug Targets; 2017; 17(9):782-805. PubMed ID: 28201977
[TBL] [Abstract][Full Text] [Related]
3. Treating Multiple Myeloma in the Context of the Bone Marrow Microenvironment.
Ho M; Xiao A; Yi D; Zanwar S; Bianchi G
Curr Oncol; 2022 Nov; 29(11):8975-9005. PubMed ID: 36421358
[TBL] [Abstract][Full Text] [Related]
4. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
Chung C
Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
[TBL] [Abstract][Full Text] [Related]
5. Bone marrow microenvironment in multiple myeloma progression.
Manier S; Sacco A; Leleu X; Ghobrial IM; Roccaro AM
J Biomed Biotechnol; 2012; 2012():157496. PubMed ID: 23093834
[TBL] [Abstract][Full Text] [Related]
6. Targeting the bone marrow microenvironment in multiple myeloma.
Kawano Y; Moschetta M; Manier S; Glavey S; Görgün GT; Roccaro AM; Anderson KC; Ghobrial IM
Immunol Rev; 2015 Jan; 263(1):160-72. PubMed ID: 25510276
[TBL] [Abstract][Full Text] [Related]
7. The impact of the bone marrow microenvironment on multiple myeloma (Review).
Hou J; Wei R; Qian J; Wang R; Fan Z; Gu C; Yang Y
Oncol Rep; 2019 Oct; 42(4):1272-1282. PubMed ID: 31524246
[TBL] [Abstract][Full Text] [Related]
8. Extracellular vesicle cross-talk in the bone marrow microenvironment: implications in multiple myeloma.
Wang J; Faict S; Maes K; De Bruyne E; Van Valckenborgh E; Schots R; Vanderkerken K; Menu E
Oncotarget; 2016 Jun; 7(25):38927-38945. PubMed ID: 26950273
[TBL] [Abstract][Full Text] [Related]
9. Homing characteristics of donor T cells after experimental allogeneic bone marrow transplantation and posttransplantation therapy for multiple myeloma.
van der Voort R; Volman TJ; Verweij V; Linssen PC; Maas F; Hebeda KM; Dolstra H
Biol Blood Marrow Transplant; 2013 Mar; 19(3):378-86. PubMed ID: 23266741
[TBL] [Abstract][Full Text] [Related]
10. Multiple myeloma exosomes establish a favourable bone marrow microenvironment with enhanced angiogenesis and immunosuppression.
Wang J; De Veirman K; Faict S; Frassanito MA; Ribatti D; Vacca A; Menu E
J Pathol; 2016 Jun; 239(2):162-73. PubMed ID: 26956697
[TBL] [Abstract][Full Text] [Related]
11. Good Cop, Bad Cop: Profiling the Immune Landscape in Multiple Myeloma.
Sharma NS; Choudhary B
Biomolecules; 2023 Nov; 13(11):. PubMed ID: 38002311
[TBL] [Abstract][Full Text] [Related]
12. MicroRNAs and exosomes: Small molecules with big actions in multiple myeloma pathogenesis.
Pourhanifeh MH; Mahjoubin-Tehran M; Shafiee A; Hajighadimi S; Moradizarmehri S; Mirzaei H; Asemi Z
IUBMB Life; 2020 Mar; 72(3):314-333. PubMed ID: 31828868
[TBL] [Abstract][Full Text] [Related]
13. NRF2 Is One of the Players Involved in Bone Marrow Mediated Drug Resistance in Multiple Myeloma.
Yen CH; Hsiao HH
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30405034
[TBL] [Abstract][Full Text] [Related]
14. Therapeutics to harness the immune microenvironment in multiple myeloma.
Ignatz-Hoover JJ; Driscoll JJ
Cancer Drug Resist; 2022; 5(3):647-661. PubMed ID: 36176763
[TBL] [Abstract][Full Text] [Related]
15. The Immune Microenvironment in Multiple Myeloma: Friend or Foe?
Lopes R; Caetano J; Ferreira B; Barahona F; Carneiro EA; João C
Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33562441
[TBL] [Abstract][Full Text] [Related]
16. Exosomes in the Pathogenesis and Treatment of Multiple Myeloma in the Context of the Bone Marrow Microenvironment.
Chen T; Moscvin M; Bianchi G
Front Oncol; 2020; 10():608815. PubMed ID: 33251153
[TBL] [Abstract][Full Text] [Related]
17. Targeting the Bone Marrow Microenvironment.
Moschetta M; Kawano Y; Podar K
Cancer Treat Res; 2016; 169():63-102. PubMed ID: 27696259
[TBL] [Abstract][Full Text] [Related]
18. Multiple Myeloma and the Immune Microenvironment.
Kawano Y; Roccaro AM; Ghobrial IM; Azzi J
Curr Cancer Drug Targets; 2017; 17(9):806-818. PubMed ID: 28201978
[TBL] [Abstract][Full Text] [Related]
19. Osteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1.
Tai YT; Cho SF; Anderson KC
Front Immunol; 2018; 9():1822. PubMed ID: 30147691
[TBL] [Abstract][Full Text] [Related]
20. The bone marrow microenvironment enhances multiple myeloma progression by exosome-mediated activation of myeloid-derived suppressor cells.
Wang J; De Veirman K; De Beule N; Maes K; De Bruyne E; Van Valckenborgh E; Vanderkerken K; Menu E
Oncotarget; 2015 Dec; 6(41):43992-4004. PubMed ID: 26556857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
